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ABSTRACT
Deregulation of cell cycle that results in 
uncontrolled cellular proliferation is the basis of 
neoplastic process. Bladder tumors are 
heterogenous in their behavior, and it is very 
difficult to predict the clinical course in many 
patients. In order to alleviate this problem, 
attention has been focused on mutations in 
various cell cycle regulators and their association 
with tumor behavior. Mutations of the p16/CDKN2 
gene, encoding a cyclin-dependent kinase 
inhibitor, are common in bladder cancer. In 
contrast to other tumor suppressor genes, the two 
most common mechanisms for loss of p16/CDKN2 
function are homozygous deletion and loss of 
transcription associated with hyperméthylation of 
the 5'CpG island region. Recently, it is found that 
méthylation of p16/CDKN2 is potentially reversible 
with exposure to demethylating agents, such as 5- 
aza-2'-deoxycytidine, which is a well-established 
inhibitor of DNA méthylation, which may open up 
new ways to effective tumor management.
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INTRODUCTION
In an a ttem pt to identify the underly ing m echanism s of 
neoplasia  m any stud ies have surveyed tum ors and 
tum or cell lines fo r the p resence of m utations in genes 
encod ing cell cyc le -re la ted  pro te ins (1). As a result of 
these  studies, m uta tions in cell cycle genes constitute 
the m ost com m on genetic  in tum or cells. In fact, 
a lm ost all o f the tum ors have m utations in one of the 
genes invo lved in contro lling  progression trough the 
cell cycle. M a lignan t ce lls may acquire  independence
from regulatory signals tha t are norm ally required fo r a 
contro lled cell cycle progression (2).
It has shown that DNA m ethyla tion Is essential for 
norm al em bryonic deve lopm ent but a lterations in DNA 
m ethylation are also very com m on in cancer cells and 
capable of d irectly m odifying carcinogenesis. Current 
interest has focused on the potentia l o f abnorm al 
m ethyla tion  events in s ilencing tum or suppressor 
genes, and caus ing  th e ir p rog ress ive  ep igene tic  
inactivation. Recent studies have shown that it is 
poss ib le  to  re a c tiva te  th e se  d o rm an t genes by 
inh ib itors o f DNA m ethyla tion and potentia lly  restore 
growth contro l o f cells (3).
Th is  rev iew  focuses  on the  im portance  of DNA 
m ethyla tion  pa rticu la rly  in p16 /C D K N 2 in b ladder 
carcinogenesis.
Cell Cycle, Cyclin-Dependent Kinases 
and Inhibitors
Cell cycle is a care fu lly  p rogram m ed process in which 
jus t after division, the cell tha t is destined to divide 
again enters a stage called G 1 . A lte rnative  is a resting 
phase called GO. A cell in G1 next m oves into S phase, 
during  w h ich  tim e DNA rep lica tion  occurs, by a 
m echanism  w here in  each DNA strand serves as a 
tem plate fo r its own rep lication. A t the end of S phase, 
another gap phase (G2) begins, which then leads to 
actual m itosis (M). E xtrace llu la r s ignalling m olecules, 
such as peptide grow th factors, bind to specific cell- 
surface g row th-facto r receptors to m odulate the cell 
cycle. Norm al ce lls respond to these extracellu lar 
grow th s ignals princ ipa lly  during the G1 phase. These 
factors induce resting ce lls (GO) to enter the cell cycle. 
H ow ever, som e fa c to rs  are necessa ry  fo r the 
progression of ce lls from  G1 phase into S phase (DNA 
synthesis). O nce ce lls reach the G1/S transition and
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beg in  D NA syn th e s is , th e y  becom e  la rge ly  
unresponsive to extrace llu la r signals and proceed 
au tonom ous ly  th rough  D NA re p lica tion , G 2, and 
m itosis.
O ver the past few  decades, s tud ies by m any groups 
have shown that passage of ce lls th rough the cell 
cycle depends on the activ ity  o f enzym es known as 
"cyc lin -dependent k inases (Cdks)'' a nam e indicating 
tha t they becom e active on ly w hen they associa te w ith 
protein partners ca lled cyclins.
Cdks, take p lace at the core of the cell cyc le  engine 
and drive cell pro liferation forward by phosphoryla ting  
specific  substra tes in a cell cyc le -dependent fashion. 
In order to becom e active kinases, the Cdks m ust 
associa te w ith cyclins as w ell as undergo an activating 
phosphoryla tion. There are tw o types of prim ary G1 
phase cyclins; D -type cyclins and cyclin E fam ily  (4). 
The D fam ily o f cyclins assem ble into ho loenzym es 
w ith the kinase cata ly tic  subunits Cdk4 and Cdk6, 
w hile the principa l partner o f cyclin  E is Cdk2.
G1 phase progression is a lso subject to negative 
regu la tion  by a recen tly  d isco ve re d  g roup  of 
m o lecu les, the  cyc lin -d e p e n d e n t k inase inh ib ito rs  
(CKIs). The m echanism  w hereby they achieve the ir 
func tion  appea rs  to  be the  fo rm a tion  o f s tab le  
com plexes tha t inactivate the ca ta ly tica lly  opera tive  
units. Norm al contro l of ce llu la r grow th requires a 
balance betw een the  activators of cyclins and the 
inh ib itors o f the CDKs. O veractiv ity  o f the CDKs, 
w hether by excessive  production  of cyclins or loss of 
CKIs, can result in aberrant grow th of cells leading to 
cancer. CKIs fam ily  m em bers can be subd iv ided into 
two groups on the basis o f sequence hom ology. The 
firs t and p ro b a b ly  b e s t-ch a ra c te r ize d  CKI fam ily  
m em ber to be identified w as p21 (also know n as 
WAFI, C ip1, or Sdi), w hich inactiva tes the cyclin  E- 
Cdk2 com plex, the cyclin  A -C dk2 com plex, and the 
cyclin D1-, D2-, and D 3-Cdk4 com plexes (5). P21- 
WAF1 gene  encodes a cyc lin  dependen t kinase 
inh ib itor and m ediates tum or suppressor gene p53- 
induced cell cyc le  arrest. O verexpression of p21- 
WAF1 suppresses pro life ra tion  and grow th of tum or 
cells in vitro, as well as in vivo (6). A nother m em ber of 
th is group is p27/K ip1, w hich inactiva tes the sam e 
subset o f cyc lin -C dk com plexes as p21 . The gene 
encoding p21 m aps to chrom osom e 6p21.1, and the 
gene encoding p27 m aps to chrom osom e 12p12- 
12p13. T he  o th e r C KI su bg roup  inc ludes  th ree  
m em bers: p16 (IN K 4 A /M T S 1 /C D K N 2 ) (7),
p15(IN K 4B /M TS 2) (4), and p18 (8).
T he  p16 gene  has been  found  to  be m u ta ted  
frequently in a varie ty  of hum an cancers. It is located 
at 9p21 and encodes a 16-kD prote in ; w hich is an 
in h ib ito r o f cyc lin  D -C dk4  and cyc lin  D -C dk6
co m p le xe s  requ ired  fo r R e tin o b la s to m a  p ro te in  
phosphory la tion  (9,10). Loss of p16 by 9p21 deletion 
or m utation a llow s cyc lin /C D K  com plexes to  proceed 
w ith phosphory la tion  o f Rb w hich inactiva tes th is gene. 
In m alignant cells, the  cell cyc le  contro l pathw ay 
governed by the D -type cyc lins  is the  one tha t is m ost 
com m only m utated in tum or ce lls. In norm al cells, the 
positive  effects o f cyclin  D com pexes on cell cycle 
p rogress ion  are coun te rac ted  by the  p16 /C D K N 2 
fam ily  o f C dk-inh ib ito r prote ins.
Genetic Alterations and DNA  
Hypermethylation in Bladder Cancer
M olecu lar and cytogene tic  abnorm alities  of 9p21 have 
been reported in severa l m a lignanc ies and tum or- 
derived cell lines, includ ing m elanom a (21), g liom a
(12), leukem ia (13), lung cance r (14), head and neck 
sq u a m o u s  ce ll c a rc in o m a  (25), sq u a m o u s  cell 
ca rc in o m a  o f b la d d e r (16) and  tra n s it io n a l ce ll 
ca rc inom a of the b ladder (17). It has recently been 
dem onstra ted  tha t the p16 /C D K N 2 cell cycle  regulator 
gene m ay be inactiva ted by m ultip le  m echanism s, 
in c lu d in g  m u ta tion , d e le tio n , and m e thy la tion . 
C ytogene tic  ana lys is  o f b ladder cance r ce lls  has 
revealed tha t they  conta in  nonrandom  chorom osom al 
abnorm alities, m ain ly m onosom y of ch rom osom e 9 
(18). It w as show n tha t loss of ch rom osom e 9 is the 
m ost frequent a lte ra tion  in urothe lia l transitiona l cell 
ca rc inom a (19).
It has p rev ious ly  been show n tha t a lle lic  loss of 
chrom osom e 9 is poss ib ly  an early and com m on event 
in b ladder carc inogenes is , and absence  of b lood group 
antigen expression is p red ic tive  in de fin ing  the tum or 
behavio r (20). In the  p resence  of ch rom osom e 9 loss, 
tum or recurrence and /o r p rogress ion  w as observed in 
83%  of b ladder cancers. M o lecu la r gene tic  s tud ies of 
b ladder tum ors  have show n fu rthe r tha t LOH in 
chrom osom e 9 sequences is a frequen t occurrence in 
p a p illa ry  su p e rfic ia l tu m o rs  (21). Loss of 
he terozygosity  on 9p21, w here  the p16 /C D K N 2 and 
the p15-IN K 4B  cell cyc le  regu la to r genes are located, 
is a com m on genetic  a lte ra tion  in b ladder cancer (22).
O rlow  et al (23) reported an overa ll frequency of 
de le tions and rearrangem ents  fo r the  p16 and p15 
genes in b ladder cancer of app rox im ate ly  18% each. 
The ir s tudy did not de tec t any po in t m uta tions e ither in 
exon 2 of the  p16 gene  or in exons 1 and 2 of the p15 
gene (75%  of the to ta l cod ing sequence). Th is study 
also revealed tha t the p15 gene  and p16 gene, which 
are ad jacen t to  one another, w ere  a lm ost always 
de le ted together. A lthough, m ost o f the p16/C D KN 2 
hom ozygous de le tions a lso inc lude the  p15-IN K 4B  
locus, no in tragen ic m uta tions in p15-IN K 4B  have
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beed reported to date. H om ozygous de letions have 
beed described  to  occur p re ferentia lly  in low-grade 
b ladder carc inom a. It should be em phasized that only 
Ta and T1, but not Tis, lesions showed deletions of 
e ither p16 or p15. In a recent study (24), it was 
dem onstra ted  tha t p16 a lte ra tions occur independent 
o f p53 m uta tions. Because p53 alterations com m only 
occur in T is b ladder tum ors (25), it can be a hypothesis 
tha t b ladder ca rc inogenes is  m ight develop through two 
d is tinc t m o lecu la r pa thw ays (26).
The described tum or suppressor genes m ight be part 
o f c h e c k p o in t pa th w a ys  ensu ring  the  accu ra te  
transm iss ion o f gene tic  in form ation during cell division. 
In the case of inactiva tion  of these  genes by m utations, 
both prom oting  cell pro life ra tion  and accum ulation of 
genom ic errors lead to c lonal evo lution of cancer cells. 
D eletions at 9p21 have been reported in m any human 
tum or types, includ ing nearly 50%  of b ladder cancers 
(7). Several stud ies show  hom ozygous de letions at 
gp21/C-DKN2 in both uncultered and cultured bladder 
cancers (8), m aking C DKN2 a strong candidate tum or 
supressor gene.
DNA Hyperméthylation
Recently, m éthyla tion, an ep igenetic event, has been 
associa ted w ith the loss of C DKN2 expression in 
several cancers  (27). DNA m éthyla tion in eukaryotic 
DNA is a norm al postrep lica tive  process and occurs at 
the 5 ’ -position of cytos ine residues in the m ajority of 
CpG d inucleotides. This m odification is associated 
w ith  gene  a c tiv ity  and is essen tia l fo r norm al 
m am m alian  deve lopm ent. D iscrete regions of CpG- 
rich sequences w ithous m éthyla tion are c lustered as 
CpG is lands. These  is lands have been shown to be 
often associa ted  w ith p rom oter reg ions of genes (28).
A lte ra tions of DNA m éthyla tion  pa tte rns in these 
reg ions have im portant regulatory effects on gene 
expression. H yperm éthyla tion  of CpG islands have 
been show n to be associa ted w ith structural a lterations 
in chrom atin  and transcrip tiona l repression (29). CpG 
islands are com m on ly  associa ted w ith housekeeping 
genes and m ay regu la te  the ir transcrip tiona l activities. 
H owever, a lte ra tions in the  m éthyla tion status of CpG 
is la n d s  du rin g  m a lig n a n t tra n s fo rm a tio n  m ay be 
corre la ted w ith transcrip tiona l changes in a num ber of 
genes associa ted w ith grow th regulation, and it is 
possib le  tha t o ther genes involved in cell cycle control 
m ay a lso  be in flu e nce d  by these  e p igene tic  
m echanism s.
A pproxim ate ly  1% of cytos ines in vertebra te  DNA are 
m ethyla ted at CpG d inuc leo tides (30). The presence of
5-m ethy lcy tos ine  at CpG d inucleo tides may contribute 
to tum origenes is  e ither by genera ting  po in t m utations
or by altering gene expression (31). Deam ination of 5- 
m ethylcytosine form s thym id ine and generates a G-T 
m ism atch which, if not reparied, fu rther produces a A 
to U transition. A considerable varia tion also has been 
reported in m utational type at CpG sites among 
d iffe ren t types  o f cancer. N everthe less, aberrant 
m é thy la tion  of p ro m o te r reg ions  resu lting  in 
inactivation of tum or suppressor gene expression has 
been proposed to be an im portant m echanism  in 
cancer progression (32). In som e tum ors, méthylation 
appears to supplem ent de le tion or m utation, resulting 
in hom ozygous gene inactivation (33). The 5' region of 
C DKN2 conta ins num erous CG d inucleotides (termed 
"CpG  is land") th a t are unm e thy la ted  in the 
transcrip tionally active gene (32).
The changes in DNA m éthyla tion tha t accom pany 
ca rc in o g e n e s is  have been sum m arized  in m any 
studies. Decreases in the overall content o f 5-m Cyt 
(34), dém éthyla tion of specific  loci (35). de novo 
m éthylation of CpG is lands (36), and increased levels 
of DNA m ethyltransferase enzym e (37) have all been 
observed. These observations co llective ly have shown 
tha t m é thy la tion  cha n g e s  are h igh ly  cons is ten t 
features of carciogenesis.
A va rie ty  o f te ch n iq u e s  have been p rev ious ly  
developed that can be used to investigate patterns of 
DNA m éthylation, such as genom ic sequencing (38), 
P C R -based  m é thy la tion  ana lys is  (39), S ou thern  
b lo tting , and m é thy la tion  sens itive  A P-PC R  (40). 
However, none of these can be used to isolate specific 
and unknown DNA sequences from  genom ic DNAs 
that are d iffe rentia lly  m ethyla ted between norm ai and 
tum or tissues. G lobal changes in DNA méthylation 
patterns are known to occur during tum origenesis, and 
gene silencing has been associa ted w ith m éthylation 
of CpG islands located in, or near, prom oters and 5' 
regulatory regions. W ith the exception of genes on the 
inactive X chorom osom e (41), Alu and 11 sequences 
(42), and som e im printed genes (43), CpG islands are 
usually unm ethyla ted in norm al som atic  cells. In 
contrast, w idespread m éthyla tion of CpG islans occurs 
on autosom al genes during oncogenic transform ation. 
A berrant m éthyla tion w ith in  5 ’ prom oter region is 
associated w ith a transcrip tiona l s ilencing of CDKN2 in 
m any cancer cell lines as w e ll as in lung, b ladder, and 
colon tum ors (27). This event is associated w ith a 
tightly com pacted chrom atin  conform ation  around the 
C DKN2 prom oter (29). G onzalez et al (27) showed the 
m é thy la tion  s ta tus  and e xp ress ion  leve ls  o f the 
p16/C D KN 2 tum or suppressor gene and the p15- 
INK4B cell cycle regu la to r in norm al tissues, cell lines, 
and b ladder and co lon cancer; and they concluded that 
expression of the p16/C D KN 2, but not expression of 
the p15 INK4B cell cyc le  regulator, is contro lled by 
m éthyla tion of its 5' CpG island, and that de novo 
m é thy la tion  of th is  is land  is a m echan ism  for
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p16/C D K N 2 inac tiva tion  in b ladde r cancer. They 
indicated tha t the 5' CpG island o f the p16/C D KN 2 
TSG is frequently  m ethyla ted in th is tum or type. The 
high frequency (67% ) of uncultered tum ors show ing de 
novo m éthyla tion of the p16/C D KN 2 5' CpG island 
could expla in  the low  rate at w hich p16 hom ozygous 
d e le tions  and in tra g e n ic  m u ta tions  are found  in 
b ladder cancer.
They po inted out that, in contrast to  squam ous cell 
carcinom a of the b ladder in w hich p16 is frequently  
de le ted (15), de novo m ethyia tion o f the 5' CpG island 
of p16/C D KN 2 m ay be a m ore com m on m echanism  of 
in a c tiva tion  o f th is  tu m o r su p p re sso r gen e  in 
transitional cell ca rc inom a (TCC). They also show ed 
tha t the  m é thy la tion  o f the  5 ’ CpG is land  of 
p16/C D KN 2 occurred not only in b ladder tum ors and 
b ladder cell lines but also in norm al co lon mucosa.
Jarrard et al (44), show ed that 14% of prim ary prostate 
tum ors  d e m ons tra ted  a be rran t m é thy la tion . T hey  
po inted to the  absence of p16 /C D K N 2 m éthyla tion  in 
norm al, BPH, and sem inal vesic le  tissues suggesting 
tha t m éthyla tion is an event associa ted w ith neoplastic 
tra n s fo rm a tio n . R ecen t e v id e nce  ac tu a lly  
dem onstrates tha t abnorm al hyperm éthyla tion  of CpG 
is lands  ex is ts  in a va rie ty  of hum an neop las ia , 
com m only in solid tum ors, including transitional cell 
carc inom a of the b ladder (67% ), b reast carcinom a 
(31% ), g liom a (24% ), and co lorecta l ca rc inom a (10- 
40% ). S om e s tud ies  a lso  show ed  tha t 
hyperm éthyla tion of the p16/C D KN 2 prom oter region 
is a frequent and early occurring event during the 
process o f neop lastic  progression in u lcerative colitis. 
(45). In th is  study Hsieh et al. po in ted out tha t 
p16 /C D K N 2 p rom o te r m é thy la tion  is a cand ida te  
b iom arker in the  surve illance of patients w ith u lcerative 
co litis  and p1 6 /C D K N 2  re p re ss io n  by p rom o te r 
m éthy la tion  has a m a jo r ro le  in the p rocess of 
neoplastic progression in th is  group of patients.
DNA Hyperméthylation Inhibition
T here  are seve ra l fe a tu re s  o f the  abnorm a l 
m éthyla tion  pa tte rns in tum or ce lls  m aking them  
attractive  ta rge ts  fo r the rapeu tic  in tervention . The 
grow th-regu la ting  genes are present in a suppressed 
form, that m akes it theore tica lly  possib le  to restore 
expression and hence re instate grow th contro l. In 
addition to this, genes silenced by m éthyla tion errors 
are very sensitive  to reactivation by inh ib itors o f DNA 
m éthylation such as azacytos ine nucleosides (30).
T he  e p ig en e tic  in a c tiva tio n  o f p16 /C D K N 2  gene 
expression is po tentia lly  revers ib le  w ith exposure  to 
dem ethyla ting agents, such as 5-aza-2 '-deoxycytid ine , 
w h ich  is a w e ll-e s ta b lish e d  in h ib ito r o f DNA
m é th y la tio n  (46). T h is  agen t, in h ib its  5- 
m ethyltransferase, and induces C D K N 2 reexpression 
in several tum or types, includ ing b ladder cell lines 
conta in ing  aberrant m éthyla tion . C aste llo  et al (29) 
dem onstra ted  tha t th is  reexpress ion  is associa ted w ith 
a re laxation  of tigh tly  com pacted  chrom atin  in the 
CDKN prom oter region. B ender et al. (3) show ed that 
a fte r exposing seven hum an tum or cell lines and two 
hum an fib rob last cell stra ins to the  dem ethyla ting  
agen t, 5 -a z a -2 '-d e o x y c y tid in e  (5 -A za -C d R ), to  
de term ine w he the r the s ilencing of g row th-regu la to ry  
genes by de novo m éthyla tion  in im m orta lized cell 
lines could be reversed, poss ib ly  restoring  grow th 
contro l, th is agent suppressed  ce llu la r grow th in all 
seven tum or lines but not in fib rob las t stra ins. They 
concluded that 5 -A za-C dR  m ay s low  the  grow th of 
tum or ce lls by reactiva ting  g row th -regu la to ry  genes 
silenced by de novo m éthyla tion .
B ender et al. a lso reported tha t p16 induction  and 
g row th  suppress ion  by 5 -A za -C dR  tre a tm e n t are 
heritab le  and dose  dependent, supporting  find ings by 
C as te llo  e t al. in w h ich  5 -A za -C d R  m ed ia ted  
p16/C D KN 2 expression  w as heritab le  in vitro. Jarrard 
et al. in an a ttem pt to  eva luate  the  effect o f this 
dem ethyla ting  agent on transcrip tion , trea ted PC3, 
PPC1, and TSU -P R 1, cell lines w ith dense 5' CpG 
island m éthyla tion , fo r 5 days. R eexpression of the 
p16 /C D K N 2 tra n sc rip t by R T-PC R , and a partia l 
dém é thy la tion  of the  5 ’ C pG  is land  in S outhern  
analysis, m orpho log ic  a lte ra tions in cu ltu re  consisting 
of c e llu la r a g g re g a te s  fo rm a tio n , and  dec reased  
grow th rate w ere  noted in th is  study (47).
H erm an et al. (33), at the  basis o f the  associa tion  of 
hyperm éthyla tion  in the 5' p rom ote r reg ion w ith lack of 
transcrip tion  o f the norm al m R NA, exam ined  cell lines 
of breast, prostate, and co lon cance r fo r p16/C D KN 2 
expression by RT-PCR. They dem onstra ted  tha t no 
m ethyla ted cell line  expressed  the  expected  p16 
product. In contrast, norm al fem a le  b reast tissue  and 
th ree  o f fo u r te s te d  no rm a l co lon  sa m p le s  had 
d e te c ta b le  p16 m essage . To co n firm  th a t DNA 
m éthyla tion  b locked transcrip tion , they trea ted the 
co lon cancer cell lines w ith  the dem ethy la ting  agent, 
ant they noticed tha t both co lon cancer cell lines had 
de tectab le  p (p16) 16 m R N A  a fte r trea tm ent w ith 5- 
A za-C dR . And also they po in ted tha t the  aberrant DNA 
m éthyla tion  is essentia l fo r m a in ta in ing  transcrip tiona l 
s ilencing. All these  resu lts  suggest cance r therap ies in 
w hich g row th -regu la to ry  genes (like p16) s ilenced by 
de novo m éthyla tion  are reactived by 5-A za-C dR , 
e ffective ly  suppressing the  g row th  of hum an tum or 
cells.
H owever, accord ing  to Jones (47) in sp ite  o f the ir 
po tency and spec ifity  fo r inh ib ition  o f DNA m éthyla tion, 
th e  ch e m ica l in s ta b ility  o f 5 -a z a -n u c le o s id e s  in
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aqueous so lu tion  and present suspicion about the 
ca rc iogenec ity  and m utagenecity  o f 5-Aza-CdR make 
it un like ly tha t these  drugs will find w idespread clinical 
use. There fore , the re  is a need to search for other 
inh ib itors o f the DNA m ethyltransferase.
Conclusion
As the genes and pathw ays govern ing cell cycle 
contro l are better understood, the ir invo lvem ent in 
hum an cancer becom es clearer. How these m olecules 
in te ra c t w ith  one  ano the r to  con tro l norm al cell 
pro life ra tion  and role o f the ir loss in contribution to 
tum origenes is  have not been understood exactly, and 
may be the m ost im portant question will be w hether 
they constitu te  useful therapeutic  targets in cancer 
cells. C hanges in the  DNA m ethyla tion m achinery and 
a lte ra tions in DNA m ethyla tion  patte rns and levels are 
very com m on in cancer cells, including b ladder cancer. 
A h igh ly cons is ten t find ing in cancer cells is that the 
CpG is lands o f g row th-regu la to ry  genes are often 
m ethyla ted, in con trast to the  situation in the ir normal 
counterparts . These  changes could play a d irect role in 
the  induction of po in t m utations tha t inactivate tum or 
suppressor genes. Th is  may also be an im portant 
aspect of fu ture  the rapeu tic  approaches.
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